AEROVATE THERAPEUTICS INC (AVTE)
US0080641071 - Common Stock
Noteworthy Thursday Option Activity: AVTE, BYON, DASH
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q2 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aerovate Therapeutics (NASDAQ:AVTE) just reported results for the second quarte...
Aerovate Therapeutics to Explore Strategic Alternatives
Aerovate Therapeutics to Explore Strategic Alternatives
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and...
The 3 Hottest Stock Downgrades From Last Week
Explore the experts' latest surprising stock downgrades amid significant market shifts and analyst adjustments.
Monday Sector Laggards: Paper & Forest Products, Biotechnology Stocks
Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke
The company was working on a treatment for pulmonary arterial hypertension, a form of high blood pressure in the lungs.
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses...
Notable Friday Option Activity: AVTE, FND, REI
Notable Wednesday Option Activity: AVTE, MDGL, BASE
AVTE Makes Notable Cross Below Critical Moving Average
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024...
Commit To Buy Aerovate Therapeutics At $10, Earn 171.1% Annualized Using Options
Aerovate Therapeutics Enters Oversold Territory (AVTE)
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aerovate Therapeutics (NASDAQ:AVTE) just reported results for the first quarter...
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial...
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, in San Diego, CA. The presentation will provide baseline characteristics from patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension.
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aerovate Therapeutics (NASDAQ:AVTE) just reported results for the fourth quarte...
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial...
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on...
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial ...